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INTRODUCTION
Immune-mediated hemolytic anemia (IMHA) re-
sults from an immune-mediated destruction of red
blood cells (RBCs) that causes a decrease in the total
RBC mass and often leads to life threatening anemia.
In dogs, IMHA is a frequent cause of anemia. In cats
however, IMHA has been reported less often and, in
contrast to dogs, the disease occurs most often secon-
dary to a known underlying cause. 
When an underlying cause is found to trigger the
immune system to destroy the RBCs, a diagnosis of se-
condary IMHA is established. When, despite extensive
research, no underlying cause of the immune-mediated
destruction of the RBC’s can be identified, a diagnosis
of primary IMHA is made. Despite this clinical sub-
division, it is not excluded that in primary IMHA there
is a trigger to the immune-mediated RBC destruction.
In this review a complete summary of IMHA in cats
and the differences seen between cats and dogs are pro-
vided. 
PATHOPHYSIOLOGY
The removal of aged RBCs occurs mainly within
the spleen and to a lesser extent in the liver by cells of
the mononuclear phagocytic system (MPS) that iden-
tify antibodies directed against senescent membrane
antigens, such as the band 3 antigen (Cotter, 2001).
IMHA is a pathologic process that results in the pre-
mature destruction of RBCs that are coated with im-
munoglobulins, complement or both. The disease is
Immune-mediated hemolytic anemia (IMHA) in cats -
part 1: a review
Immuungemedieerde hemolytische anemie bij katten -
deel 1:  een literatuuroverzicht
G. Paes, D. Paepe, J. Veldeman, M. Campos, S. Daminet
Department of Small Animal Medicine and Clinical Biology
Faculty of Veterinary Medicine, Ghent University
Salisburylaan 133, B-9820, Merelbeke, Belgium
geertpaes@ugent.be
ABSTRACT
In contrast to dogs, immune-mediated hemolytic anemia is rarely seen in cats and occurs most often
secondary to an underlying infectious, neoplastic or inflammatory process. Clinical symptoms are often vague
and are caused by severe anemia and the effect of hypoxia on organ systems. Laboratory abnormalities in cats
with IMHA are comparable to those seen in dogs, with the exception of spherocytes, which are difficult to
identify in cats. The diagnosis is based on hemolytic anemia in combination with a positive ‘true’
autoagglutination and/or a positive Coombs test. A search for underlying causes should always be performed
and, because infections with hemotrophic mycoplasma species are the most important underlying cause for
IMHA in cats, a polymerase chain reaction test to detect these bacteria should be carried out. Treatment
consists of immunosuppressive drugs, providing oxygen-carrying solutions, treating underlying causes and
supportive care. In cats, IMHA carries a better prognosis than in dogs, although relapses are seen in equal
frequency. 
SAMENVATTING
Immuungemedieerde hemolytische anemie (IMHA) komt zelden voor bij katten en ontstaat meestal secundair
aan onderliggende infectieuze, tumorale of inflammatoire processen. De klinische symptomen van IMHA zijn meestal
vaag en worden veroorzaakt door erge anemie met secundair hypoxie van organen. De bevindingen bij labo-
onderzoek zijn vergelijkbaar met deze die gezien worden bij honden, met uitzondering van de sferocyten, die bij
katten moeilijk te identificeren zijn. De diagnose is gebaseerd op een combinatie van hemolytische anemie met een
positieve ‘echte’ autoagglutinatie- en/of coombstest. Verder onderzoek naar onderliggende oorzaken is steeds
noodzakelijk. Aangezien infecties met hemotrofe mycoplasmen de belangrijkste oorzaak van IMHA bij katten zijn,
is het uitvoeren van een PCR-test ter detectie van deze  bacterie aangewezen. 
De behandeling bestaat uit het behandelen van onderliggende ziekten, het toedienen van immunosuppressieve
geneesmiddelen en een ondersteunende behandeling met ondermeer bloedtransfusies. Katten met IMHA hebben een
betere prognose dan honden met deze ziekte, hoewel het percentage patiënten dat hervalt, gelijk is voor beide
diersoorten. 
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caused by a type II hypersensitivity reaction in which
antibodies (mainly IgG and IgM) are produced against
normal RBCs (primary IMHA) or against RBCs of
which surface antigens are altered through interaction
with secondary causes such as drugs, infectious disea-
ses and neoplasia (secondary IMHA) (McCullough,
2003). Red blood cell bound IgM antibodies are more
frequently detected in cats with IMHA than in dogs
with IMHA in which IgM antibodies are only present
in about 8% of the cases (Klag et al., 1993). In one
study, IgM antibodies were detected in 8 of 15
Coombs-positive cats with primary IMHA (Kohn et al.,
2006). Because IgM is a large pentameric molecule that
can directly agglutinate RBCs, autoagglutination, that
persists after washing the RBCs (‘true’ autoagglutina-
tion), is often seen in cats with IMHA (in 4 of the 19
cats with IMHA in a study by Kohn et al. (2006))
(Gunn-Moore et al., 1999; McCullough, 2003; Kohn et
al., 2006). Furthermore, complement activation is
stronger for IgM immunoglobulins than for IgG iso-
type. IgG is a monomeric molecule with less aggluti-
nation capability. Hemolysis of antibody-coated RBCs
can occur intra- or extravascularly in liver and spleen.
Intravascular hemolysis is uncommonly seen in dogs
(4% to 9%) and has not been reported in cats with
IMHA yet (Klag et al., 1993; Engelbrecht et al., 2002;
Kohn et al., 2006). During phagocytosis of RBC by
cells of the MPS (extravascular hemolysis), RBCs
(normal RBC diameter: 7.0 µm in the dog and 5.8 µm
in the cat) loose their redundant membrane, which re-
sults in the formation of spherocytes which are smal-
ler than normal RBCs (less than two thirds of the nor-
mal diameter) and lack a central pallor (Walker, 1999)
(Figure 1). In dogs, large amounts of spherocytes on a
peripheral blood smear are highly indicative for IMHA.
In cats however, spherocytes are difficult to identify,
because normal cat RBCs are smaller and they often do
not have a central pallor (Kohn et al., 2006).  
In contrast to dogs, in which primary IMHA repre-
sents 60-75% of all IMHA cases, most presentations of
feline IMHA are secondary (McCullough, 2003). Se-
condary IMHA in cats can be triggered by infectious
agents (e.g. feline leukemia virus (FeLV), feline in-
fectious peritonitis (FIP), Mycoplasma hemofelis, Ba-
besia felis), by drugs (eg. propylthiouracil), by neo -
plasia (eg. lymphoma), by inflammatory conditions
(e.g. chronic cholangitis), by blood transfusions with
incompatible donors and in rare cases by systemic lu-
pus erythematosus (SLE) (Gunn-moore et al., 1999;
Messick, 2003; McCullough, 2003; Penzhorn et al.
2004; Norris et al. 2005; Kohn et al., 2006).
Pure red cell aplasia (PRCA) is a well-recognized
form of IMHA that occurs in both dogs and cats and
that is characterized by a severe non-regenerative ane-
mia and erythroid aplasia in the bone marrow (Gunn-
moore et al., 1999; Zini et al., 2007; Weiss, 2008). Pri-
mary PRCA in cats is probably an immune-mediated
disorder (Stokol, 1997; Weiss, 2008). A study in dogs
with PRCA has shown antibodies capable of suppres-
sing erythropoiesis (Weiss, 1986). Secondary PRCA
occurs commonly in cats infected with feline leukemia
virus (Abkowitz, 1987).
UNDERLYING CAUSES FOR IMHA IN CATS
Because IMHA is most often secondary in cats, a
summary of the most important underlying causes will
be given. Only when, despite extensive workup, no un-
derlying cause can be identified, a diagnosis of primary
IMHA is established.
Infectious agents
From the infectious agents, hemotrophic myco-
plasma infections (formerly Haemobartonella) have
been most frequently associated with IMHA in cats
(McCullough, 2003). Although significant geographic
variations exist, the overall prevalence of hemotro-
phic mycoplasma species in the blood of cats, measu-
red by a real-time polymerase chain reaction (RT-PCR)
test, has been reported to be as high as 12.5% and
18.5% in Switzerland and the United Kingdom, res-
pectively. In addition, no significant difference in hem-
oplasma prevalence between healthy and ill cats was
found (Messick, 2003, Willi et al., 2006). Hemotrophic
mycoplasmas are epicellular RBC bacteria and the
route of transmission of these parasites is not yet com-
pletely understood (Duin et al., 2009). Four existing ty-
pes (Mycoplasma hemofelis, Candidatus Mycoplasma
hemominutum, Candidatus Mycoplasma turicensis and
Candidatus Mycoplasma hematoparvum) have been
described in cats (Tasker, 2003; Willi, 2006), but only
Mycoplasma hemofelis can cause severe hemolytic
anemia, also known as feline infectious anemia. The
other strains cause no or only minimal clinical illness
in healthy cats. However, when complicated by co-in-
fections with other strains or with retroviral infections
or when the animal is immunosuppressed, these strains
can also cause a significant drop in packed cell volume
Figure 1. Diff-Quick stained blood smear of an anemic
dog diagnosed with primary IMHA showing a sphero-
cyte, a polychromatic cell (immature red blood cell or re-
ticulocyte), an eosinophil and a rubricyte (red blood cell
precursor).
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(PCV) (Westfall et al., 2001; Messick, 2003; Willi et
al., 2006). The mechanism by which Mycoplasma
hemofelis induces anemia, is partially based on a direct
damage of the RBC. However, immune-mediated in-
jury of RBCs appears to be more important (Harvey,
2006). Co-infections with FeLV occur and generally re-
sult in more severe anemia (Messick, 2003). Other in-
fectious agents that can cause IMHA in cats are FeLV
(Gunn-Moore et al., 1999; Kohn et al., 2006) and ra-
rely FIP and Babesia felis (Penzhorn et al., 2004; Nor-
ris et al., 2005). 
Drugs
Several drugs (e.g. propylthiouracil, methimazole,
famotidine) have been reported to cause IMHA in cats,
although scientific evidence that proves the association
between IMHA and the drug administration, most of-
ten lacks (Peterson et al., 1984; de Brito Galvao et al.,
2008). The intravenous (IV) administration of famoti-
dine has been anecdotally associated with feline IMHA
(Plumb, 2002). Therefore, some veterinarians recom-
mend injectable famotidine only by subcutaneous route
in cats. The risk of such reaction has been evaluated in
a recent retrospective study, which could not demon-
strate a decrease in the PCV after IV famotidine (de
Brito Galvao et al., 2008). The authors therefore con-
cluded that the IV route appeared to be safe if famoti-
dine was administered over 5 minutes.
Neoplasia
Neoplastic diseases, such as lymphoma, were pre-
viously associated with IMHA in cats. Gunn-moore et
al. (1999) reported IMHA in 2 sibling cats associated
with multicentric lymphoblastic infiltration. They also
suggested a genetic predisposition in these animals.
Vaccination
Finally, vaccination (< 1 month) in dogs has been
suggested to trigger immune-mediated diseases, such
as IMHA and polyarthritis (Duval et al., 1996; Kohn et
al., 2003). Although recent vaccination against calici-
virus was reported to cause polyarthritis in cats, no as-
sociation between vaccination and IMHA has been
described in cats (Dawson et al., 1993; Kohn et al.,
2006).
EPIDEMIOLOGY
In a recent study, primary IMHA was mainly seen
in young (average age of 3.2 years) domestic shorthair
cats (59%). Furthermore, male cats (58%) were pre-
disposed and the majority of the cats were kept strictly
indoors (73%). According to these studies, outdoor
access does not seem to be a risk factor for primary
IMHA in cats. Also in other studies, a predisposition for
young, male cats has been described for primary IMHA
(Gunn-moore et al., 1999, McCullough, 2003). In con-
trast to cats, mainly young to middle-aged female
spayed dogs are affected by IMHA (McCullough,
2003; Miller et al., 2004). 
Feline PRCA is consistently diagnosed at a young
age (8 to 36 months) (Stokol et al., 1999; Zini et al.,
2007).
Secondary IMHA may affect cats of any age (Gunn-
moore et al., 1999). Infections with hemotrophic myco -
plasmas have been associated with male gender, outdoor
access and old age (Willi et al., 2006).
CLINICAL PRESENTATION
Clinical signs may be acute or chronic and are of-
ten non-specific. In a study by Kohn et al. (2006), in
19 cats with primary IMHA the following signs were
reported by the owners: lethargy (n=19), inappetence
(n=13), pica (n=5), vomiting (n=2), pruritus (n=1),
dyspnea (n=1), epistaxis (n=1), polydipsia (n=1) and
obstipation (n=1). The cats were sick for a median of
8.5 days before presentation. 
On physical examination, most abnormalities are
caused by severe anemia and the effect of hypoxia on
organ systems, such as liver, lungs, heart, kidney and in-
testines (McCullough, 2003). The physical examination
of the previously described 19 cats with primary IMHA
revealed pale mucous membranes (n=19), icteric mu-
cous membranes (n=2), hypothermia (n=2), fever (n=4),
a mild to moderate systolic heart murmur (n=8) and a
mild generalized or focal lymphadenopathy (n=3). 
In dogs, clinical symptoms of IMHA are compara-
ble to those seen in cats. Vague signs, such as weak -
ness, anorexia, pigmenturia, vomiting and diarrhea are
mainly reported by the owner (Reimer et al., 1999;
Piek et al., 2008). On physical examination, almost all
dogs with IMHA have pale mucous membranes. Icte-
rus, cranial abdominal organomegaly and systolic heart
murmur are also frequent clinical signs, each present in
50% of the patients with IMHA. In approximately
30% of the dogs with IMHA, tachycardia and tachy -
pnea are present (Reimer et al., 1999; Piek et al.,
2008). 
CLINICAL PATHOLOGY FINDINGS
Complete blood cell counts (CBC) and biochemis-
try profile most often reflect an acute hemolytic crisis
in both dogs and cats. The majority of cats (79%) with
IMHA are presented with a severe anemia (packed
cell volume (PCV) <15%). While 70 to 80 % of the
dogs with IMHA have a regenerative anemia, signs of
regeneration are absent in more than half of the cats
(58%) with IMHA (Klag et al., 1993; Reimer et al.,
1999; McManus et al., 2001; Kohn et al., 2006). Un-
til recently, 2 different hypotheses were postulated for
the presence of non-regenerative IMHA in dogs and
cats. According to the first hypothesis, it is assumed
that, when a dog or cat becomes anemic, 3 to 5 days are
required to develop a substantial reticulocyte response,
meaning that in patients with peracute IMHA reticu-
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locytes have not been released into the blood stream yet
(McCullough, 2003; Weiss, 2008). According to the se-
cond hypothesis the antibody production against RBC
precursors in the bone marrow can cause a non-rege-
nerative anemia in patients that are anemic for more
than 5 days (Kohn et al., 2006; Weiss, 2008). However,
in a recent study by Weiss (2008), in which bone mar-
row of dogs and cats with non-regenerative IMHA (of
greater than 5 days duration) and PRCA was analyzed,
it was found that the immune-mediated destruction of
bone marrow erythroid precursor cells accounted for all
of the cases of PRCA, but only for 14% of the cats and
30% of the dogs with non-regenerative IMHA. In the
other dogs and cats with non-regenerative IMHA a bone
marrow erythroid hyperplasia was present and the au-
thor postulated that the IMHA with erythroid hyper -
plasia may represent a unique subtype of IMHA. Dogs
and cats with this type of IMHA had a relatively high in-
cidence of neutropenia and thrombocytopenia and a
variety of pathological changes in the bone marrow.
Furthermore, in these patients a decreased survival of
only 60 days was observed. 
Other abnormalities that can be found in the CBC
of cats with IMHA include lymphocytosis and throm-
bocytopenia. While the majority of dogs (74%) with
IMHA have neutrophilia, often with a left shift, neu-
trophilia is only present in 10% of the cats with primary
IMHA. In the study by Kohn, a marked lymphocyto-
sis was present in the CBC of 32% and in the bone mar-
row of 86% of the cats with primary IMHA (McManus
et al., 2001; Kohn et al., 2006, Weiss, 2008). Lym-
phocytosis may indicate a chronic antigen stimulation
and has also been reported in cats with other types of
hemolytic anemia, such as pyruvate kinase deficiency
or hereditary increased erythrocyte osmotic fragility
(OF), two conditions that have been described in young
Abyssinian and Somali cats (Kohn et al., 2000; Kohn
et al., 2008). In cats with bone marrow lymphoid hy-
perplasia, it might be difficult to differentiate between
reactive lymphocytosis and chronic lymphocytic leu-
kemia (CLL). Weiss (2005) found that a normal lym-
phocyte morphology, lymphocytes of B-cell origin and
the organization of lymphocytes in aggregates are cri-
teria that suggest reactive lymphocytosis instead of
malignant lymphocytosis. In cats with chronic lym-
phocytic leukemia, lymphocytes were predominantly
of T-cell origin and were slightly larger with cleaved or
lobulated nuclei. Furhtermore, they were diffusely dis-
tributed throughout the bone marrow (Weiss, 2005).
In the study by Kohn et al. (2006), thrombocyto-
penia was found in 8 of the 19 cats with primary
IMHA. Thrombocytopenia can be caused by immune-
mediated destruction, by consumption due to diffuse
intravascular coagulation (DIC) or by sequestration in
an enlarged spleen (Kohn et al., 2006). Evans’ syn-
drome occurs when a combination of immune-media-
ted destruction of RBCs and thrombocytes is present.
In some studies, this disease has been reported to be
present in up to one third of the dogs with IMHA (En-
gelbrecht et al., 2002). However, it was only present in
1 of the 8 cats with thrombocytopenia and IMHA in the
study by Kohn et al. (2006). 
In the serum biochemistry profile, hyperbilirubine-
mia is present in the majority of cats and dogs with
IMHA and in dogs, a high bilirubin concentration is as-
sociated with a worse prognosis (Klag et al., 1993;
McCullough, 2003; Kohn et al., 2006). In the study by
Kohn et al. (2006) 7 of the 13 cats with hyperbilirubi-
nemia also had increased liver enzyme activities, indi-
cating that the hyperbilirubinemia is probably not only
a consequence of hemolysis, but probably also of liver
damage as a result of liver hypoxia (Figure 2). Other
bio chemistry abnormalities found in the 19 cats with
primary IMHA in this study were hyperglobulinemia
(n=10), hyperproteinemia (n=8), hypoalbuminemia
(n=4), increased alkaline phosphatase (AF) (n=1), in-
creased alanine transferase (ALT) (n=10), increased
aspartate transferase (AST) (n=3) and a mildly in-
creased blood urea nitrogen (BUN) (n=6). The hyper-
globulinemia probably results from chronic antigen
stimulation and has also been reported in cats with py-
ruvate kinase deficiency and in cats with hereditary in-
creased erythrocyte osmotic fragility (Kohn et al.,
2000; Kohn et al., 2008). 
A coagulation profile can reveal increased clotting
times, indicating the presence of DIC. In dogs, DIC is
seen in 12 to 45% of the dogs with IMHA (Klag et al.,
1993; Scott-Moncrieff et al., 2001; Engelbrecht et al.,
2002). In the study by Kohn et al. (2006), one cat was
diagnosed with DIC (based upon the presence of
thrombocytopenia with an increased prothrombin and
activated partial thromboplastin time) and 2 other cats
were suspected. 
Figure 2. Microhematocrite tube of a cat diagnosed with
primary IMHA showing the icteric plasma due to extra-
vascular hemolysis.
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DIAGNOSIS
The diagnosis of IMHA in anemic cats is based on
the presence of ‘true’ autoagglutination or on the de-
tection of erythrocyte-bound immunoglobulin or com-
plement with a direct Coombs test (Kohn et al., 2006). 
In IMHA, rouleaux formation is often superimpo-
sed upon agglutination. Furthermore, massive rou-
leaux formation can sometimes simulate ‘true’ auto-
agglutination. ‘Pseudoagglutination’, due to massive
rouleaux formation will only disappear after washing
the RBCs three times with physiological saline (Slap-
pendel, 1986). In the study by Kohn et al. (2006), all
of the 19 cats with IMHA showed varying degrees of
agglutination. However, after washing the RBCs three
times, the autoagglutination persisted in only 4 cats.
The direct antiglobulin test (DAT) or Coombs test
has been associated with false negative results in 42 to
63% of dogs with IMHA (Jackson et al., 1985; Reimer
et al., 1999; Quigley et al., 2001). In these studies the
Coombs test was performed as described by Slappen-
del, using antiserum that contained antidog IgM, IgG
and C3b at 37°C and at 4°C. In the study by Quigley
et al. the test was only performed at 37°C. The validity
of the Coombs test in cats was tested by Kohn et al.
(2006) and the test was negative in all healthy (n=5),
in all sick non- anemic (n=9) and in 55 of the sick ane-
mic cats (n=78). In cats with blood loss  anemia, ane-
mia due to renal failure, retrovirus infection or in-
flammatory disease and  anemia due to  hemolysis not
related to immunological processes, the Coombs test
was negative (n=55). A positive Coombs test was seen
in 18 cats. Fifteen of these cats were diagnosed with
primary IMHA and the other three with IMHA secon-
dary to lymphoma (n=2) and cholangiohepatitis (n=1).
Although the results of the Coombs test were very
promising in this study, another study using a direct
Coombs test with polyvalent antiserum found a posi-
tive test in 16 of 20 anemic cats. Of these 16 cats, only
3 cats that were infected with Mycoplasma hemofelis
had hemolytic anemia. In the other 13 cats no signs of
hemolysis were present (Dunn et al., 1984). The au-
thors concluded that positive test results in cats must be
evaluated carefully. False positive Coombs test results
may occur because circulating immune complexes
may be present due to several clinical conditions, such
as various infectious and neoplastic diseases and as a
consequence of the administration of various drugs
(Slappendel, 1986). Furthermore, false negative
Coombs test results can also be seen in dogs or cats
with IMHA and can be a consequence of improperly
prepared non-species-specific antisera or improperly
diluted antisera (Slappendel, 1986). Recently, flow
cytometry was used in a large group of dogs with dif-
ferent diseases and had a higher sensitivity (87%) and
specificity (74%) for detecting anti-RBC antibodies in
dogs with IMHA than the Coombs test (Morley et al.,
2008). To the authors’ knowledge, the use of flow
cytometry has not been evaluated in a large group of
cats yet. 
As mentioned previously, the detection of sphero-
cytes, which are pathognomonic for IMHA, is difficult
in cats. Because spherocytes have an increased osmo-
tic fragility due to a reduced volume-to-surface ratio,
measuring the RBC osmotic fragility can be an addi-
tional diagnostic tool in cats (Slappendel 1986; Kohn
et al., 2006). The osmotic fragility test can be perfor-
med in daily practice by preparing a solution equiva-
lent to 0.64% saline. Five drops of patients blood are
added to 5 ml of this solution. Afterwards, the mixture
is incubated for 5 minutes and centrifuged at 3500
rpm during 5 minutes. Osmotic fragility is normal
when intact RBCs can be seen on the bottom of the
tube and when the supernatant is clear. However, when
spherocytes are present, free hemoglobin will stain the
supernatant red. A second tube with blood of the patient
in 0.9% NaCl should be used as a control. Osmotic fra-
gility was measured in 10 of 19 cats with primary
IMHA and was increased in all cats (Kohn et al., 2006).
However, an increased osmotic fragility is not specific
for IMHA, as it can also be increased in other diseases,
such as lymphoma, hypophosphatemia, FeLV infec-
tion, renal failure or certain inflammatory diseases
(Kohn, 2006). Furthermore, an increased osmotic fra-
gility has been reported in Abyssinian and Somali cats
with hereditary increased erythrocyte osmotic fragility
(Kohn et al., 2000).
Because IMHA in cats most often occurs secondary
to an underlying disease a thorough work up to search
for underlying causes is very important. First of all, a
complete history can evaluate a recent administration
of certain drugs or vaccinations. Secondly, in any cli-
nically anemic cat with outdoor access, infectious di-
seases should be excluded. FeLV and FIV can be ex-
cluded by using commercial available enzyme-linked
immunosorbent assays (ELISA) that detect FeLV p27
antigen and FIV antibodies in blood (Arjona et al.,
2007). Because FeLV antigen may not be detected in
latent infections when the virus is integrated in bone
marrow, a polymerase chain reaction (PCR) test or
viral culture, on a bone marrow aspirate, should be per-
formed when the ELISA test is negative (Arjona et al.,
2007). Cytological examination of blood smears can
sometimes identify hemotropic mycoplasmas on the
surface of RBCs. However, the organism could only be
detected in 37.5% of cats that were experimentally
inoculated with Mycoplasma hemofelis and Candida-
tus Mycoplasma hemominutum (Westfall et al., 2001).
The low sensitivity of blood smear analysis is attribu-
table to the fact that these organisms are extremely
small and tend to become dissociated from the RBC
surface making it difficult to identify them cytologi-
cally (Westfall et al., 2001). Recently, real-time PCR
assays specific for M. hemofelis, Candidatus Myco-
plasma hemominutum en Candidatus Mycoplasma tu-
ricensis have been developed, and proved to be highly
sensitive, specific and accurate for the diagnosis of fe-
line hemoplasma infections (Tasker et al., 2003; Willi
et al., 2006). Important to remember is that cats trea-
ted with antibiotics can become PCR-negative within
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a few days after starting the treatment. However, the cat
may become chronically infected without having overt
clinical signs of infection and revert to a PCR-positive
status shortly after a discontinuation of treatment.
Therefore, a negative PCR test obtained during or
shortly after treatment with antibiotics does not al-
ways rule out the possibility of a chronic hemoplasma
infection (Messick, 2003). 
Underlying neoplastic or inflammatory processes
should be ruled out by using medical imaging techni-
ques, such as thoracic and abdominal radiography and
abdominal ultrasonography (McCullough, 2003). On
abdominal ultrasound or radiology a splenomegaly
can be detected in 42 to 60% of cats (Engelbrecht et al.,
2002; Kohn et al., 2006). Splenomegaly can result
from the infiltration of abnormal cells, inflammatory or
infectious processes, congestion or hyperplastic sple-
nomegaly (eg. related to hemolysis) and is also seen in
cats with pyruvate kinase deficiency or hereditary in-
creased erythrocyte osmotic fragility (Kohn et al.,
2006). Regarding the search for infectious causes of
IMHA, it is interesting to note that the usual clinical
workup is mainly focused on FIV, FeLV and hemotro-
pic mycoplasmas. Additionally, medical imaging of
the thorax and abdomen helps ruling out hidden infec-
tions. However, future research might indicate that
other infectious agents are involved.
Finally, cytological and/or histopathological exa-
mination of a bone marrow aspirate should be perfor-
med in cases in which there is a presence of non-rege-
nerative anemia (for a duration of more than 5 days),
when a destruction of erythroid precursors is suspec-
ted or when other cytopenias are present on the CBC
(McCullough, 2003). In some cases it can be difficult
to differentiate cats with myelodysplastic syndromes
from cats with IMHA and secondary dysmyelopoiesis.
In such cases, the clinical response to immunosup-
pressive treatment may be useful to differentiate both
diseases (Weiss, 2006). 
TREATMENT   
Immunosuppressive therapy
Immunosuppressive dosages of corticosteroids
(prednisolone, prednisone, dexamethasone and methyl-
prednisolone) are the treatment of choice for primary
IMHA in cats. Corticosteroids suppress the activity of
macrophages of the MPS, decrease the production of
immunoglobulins, inhibit the complement cascade,
enhance reticulocytosis and inhibit the production of
several cytokines necessary for T-cell generation and
function (Baschant and Tuckermann, 2010). The do-
sage of prednisolone advised in cats is 1-2 mg/kg per
os (PO) twice daily (Kohn et al., 2006). It takes 3 to 14
days before the PCV increases (McCullough, 2003).
The PCV should be checked twice weekly until it sta-
bilizes and then weekly for the duration of treatment
(McCullough, 2003). After the stabilization of the
PCV, the therapy should be tapered slowly (approxi-
mately 25% every 2-4 weeks) over a 3 to 6-month pe-
riod. Abrupt changes may lead to relapse. Evidence
about the use of cytotoxic drugs in cats is limited. In
dogs, azathioprin, a purin analogue that interferes with
DNA and RNA synthesis, is often used in the treatment
of IMHA. In cats, however, azathioprine can give bone
marrow and hepatic toxicity and therefore, the drug
should be avoided or given at a reduced dosage (0.3
mg/kg/day) (Beale et al., 1992).
Oxygen-carrying support
If the cat is severely anemic or when severe tissue
hypoxia is expected, the patient should receive an
oxygen-carrying fluid. In cats, most often whole blood
or a packed red blood cell transfusion is given. Often
more than one transfusion is needed (Kohn et al.,
2006; Weingart et al., 2004, Klaser et al., 2005). In two
recent retrospective studies evaluating the use of blood
transfusions in 91 and 126 cats from which 6 and 3
cats respectively had IMHA, blood transfusions were
well tolerated and resulted in mild transient transfusion
reactions in only 2 and 11 cats respectively (Weingart
et al., 2004; Klaser et al., 2005). It is of major impor -
tance that blood typing or cross matching are always
performed. Incompatible transfusions can result in life-
threatening complications, because of the natural
occurrence of anti-RBC antibodies in cats. Further -
more, it is advised to regularly test donor cats for the
presence of hemotropic mycoplasmas. The prevalence
of infection among feline blood donors was recently
reported to be 7.5% for Candidatus Myco plasma
hemominutum and 2.3% for M. hemofelis (Messick,
2003).    
The use of an ultrapurified, polymerized bovine
hemoglobin solution (HBOC) was evaluated in 72 cats
with anemia (Gibson et al., 2002). Because adverse ef-
fects were present in 44 cats and pulmonary  edema and
pleural effusion (due to circulatory overload) was seen
in 35% of all cats, the authors concluded that further re-
search is needed to determine the safety and the ideal
dose and rate of administration of HBOC, before the
use of the solution can be recommended in anemic cats.  
Treating for underlying diseases
Because the list of underlying causes of IMHA is
too broad to discuss all treatment protocols in detail,
only the treatment of hemotrophic mycoplasma infec-
tions will be discussed. Doxycyline (5-10 mg/kg PO
SID or BID for up to 21 days) has been the antibiotic
of choice for years for the treatment of feline myco-
plasma infections. However, doxycycline only rarely
clears this organism from the body and can cause side
effects such as oesophageal strictures in cats (Ishak et
al., 2008). More recently, the use of different types of
fluoroquinolones (enrofloxacin, marbofloxacin and
pradofloxacin) have been studied in cats infected with
M. hemofelis. Enrofloxacin (5-10 mg/kg PO SID for 14
days) was shown to be equal or superior to doxycycline
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for the treatment of mycoplasma infections, but it can
be associated with retinal degeneration in some cats (Is-
hak et al., 2008). Marbofloxacin (2.75 mg/kg PO SID
for 14 days) was administered to 14 cats that were ex-
perimentally infected with M. hemofelis and appeared
to be safe and resulted in hematological, however with-
out clinical improvement (Ishak et al., 2008). Finally,
the use of pradofloxacin (5-10 mg/kg PO SID) was
evaluated in 23 experimentally infected cats and the
drug proved to cause no side effects and have anti-M.
hemofelis effects similar to those of doxycycline. Fur-
thermore, it appeared to be more effective than doxy-
cycline at long-term clearance of the organism. Be-
cause fluoroquinolones only have to be given once
daily and because they give similar results as doxycy-
cline, the use of this class of antibiotics might be pre-
ferred to treat feline mycoplasma infections (Messick,
2003).      
Supportive care
IMHA patients can be at risk for developing gastric
ulcerations as a consequence of poor gastro-intestinal
perfusion combined with long-term administration of
corticosteroids. Therefore, gastric protectants (hista-
mine blockers, prostaglandin analogues, proton pump
inhibitors and ulcer-coating medications) may some-
times be required (McCullough, 2003). 
In contrast to dogs with IMHA, complications as
DIC and thromboembolic events do not often occur and
the use of anticoagulants is not part of the standard
treatment of IMHA in cats (Kohn et al., 2006). 
Novel treatments
Human intravenous immunoglobulin (hIVIG) is a
preparation of polyspecific human IgG that blocks the
Fc receptors of macrophages, modulates T-lympho-
cyte function, decreases natural killer cell activity,
blocks complement-mediated cell damage, neutra lizes
autoantibodies and modulates the release and function
of proinflammatory cytokines (Byrne, 2002). Although
hIVIG has been used successfully in humans and dogs
with IMHA, the use of hIVIG has only been described
in one cat with erythroid and megakaryocytic aplasia
and in one cat with erythema multiforme. Further re-
search is needed on the use of this drug in cats (Zini et
al., 2007, Byrne, 2002).
PROGNOSIS
The possibly fatal complications in dogs with pri-
mary IMHA, such as DIC and thromboembolism are
seldom seen in cats. Furthermore, cats appear to tole-
rate severe anemia better than dogs (Kohn et al., 2006).
Because of this, the mean mortality rate for IMHA is
lower in cats (24%) than in dogs, in which mortality ra-
tes of 30-70%, depending on the study, have been des-
cribed (Reimer et al., 1999; Kohn et al., 2006).
In cats with primary IMHA, relapses have been re-
ported to occur in almost 30% of cats, compared to
38% in a study of dogs (Engelbrecht et al., 2002; Kohn
et al., 2006).  
The prognosis for cats with secondary IMHA de-
pends on the underlying cause. If treated correctly, the
outcome for hemotropic mycoplasma infections in cats
is good, but recovering cats generally remain chronic
carriers and remain sensitive for new infections (Mes-
sik, 2003). 
CONCLUSION
IMHA is less frequently seen in cats than in
dogs and the majority of IMHA cases in cats are se-
condary to an underlying cause. This is also the case in
dogs, but in this species the trigger often disappears,
which makes the link with the autoimmune disease less
clear. Clinical symptoms and clinical pathological fin-
dings in cats with IMHA are comparable to those seen
in dogs, with the exception of spherocytes, which are
difficult to identify in cats. A diagnosis of IMHA is ba-
sed on the presence of ‘true’ autoagglutination and/or
a positive Coombs test. A search for possible underly-
ing causes should always be performed. Treatment
consists of immunosuppressive drugs, providing oxy-
gen-carrying solutions, treating underlying causes and
supportive care. In cats, IMHA carries a better prog-
nosis than in dogs, possibly due to a lower incidence
of thromboembolic complications.
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